Price Chart

DATE TIME TYPE PERIOD REPORTED
EPS
ESTIMATED
EPS
SURPRISE
03/25/2022* 08:30 EST Earnings Call Q4 2021 -- -- --
03/24/2022* -- Results Q4 2021 -- -0.17 --
11/15/2021 -- Results Q3 2021 -0.40 -0.19 -107.3%
08/17/2021 08:30 EST Earnings Call Q2 2021 -- -- --
08/16/2021 -- Results Q2 2021 -0.37 -0.35 -6.76%
05/18/2021 08:30 EST Earnings Call Q1 2021 -- -- --
05/17/2021 -- Results Q1 2021 -0.55 -0.51 -8.58%
03/25/2021 08:30 EST Earnings Call Q4 2020 -- -- --
*Estimated Date/Time

Earnings

Next Report Date 03/24/2022
EPS Estimate Upgrade
Last Actual EPS Upgrade

Loading chart...
Last Report Date 11/15/2021
Beat/Miss Upgrade
Return Since -45.00%
Last FQE 09/30/2021
Next FQE 12/30/2021

Profile

Edit
Liminal Biosciences Inc engages in clinical-stage research and commercialization of fibrosis treatments. The company operates in two segments: Small molecule therapeutics and Plasma-derived therapeutics. The Small molecule segment develops and commercializes treatments for lung, liver, and kidney conditions. The Plasma-derived segment sells proteins and specialty plasma in addition to developing a plasma treatment product. Liminal Biosciences does business in Canada, the U.K., and the U.S., and nearly all of its revenue comes from the plasma-derived therapeutics segment.
URL https://www.liminalbiosciences.com
Investor Relations URL http://www.prometic.com/investors/
HQ State/Province Quebec
Sector Healthcare
Industry Biotechnology
Equity Style Small Cap/Value
Next Earnings Release Mar. 24, 2022
Last Earnings Release Nov. 15, 2021
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Dividends

Dividend Per Share (TTM) --
2017
2018
2019
2020
2021
No data available
 
6.00%
4.00%
2.00%
 
Yield to Market 0.00
Yield to Sector 0.00
Yield to Industry 0.00
Last Dividend Amt. --
Dividend Frequency --
Last Ex-Dividend Date --
Yield (TTM) 0%
Forward Yield --
Payout Ratio 0.00%
Cash Payout Ratio 0.00%
Consistent Payer (5Y) No
Consistent Growth (5Y) No

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Total Returns Comparison

Edit comparables

Annual Total Returns Versus Peers

Edit comparables
Loading chart...
Name
2015
2016
2017
2018
2019
2020
2021
YTD
47.27%
-31.65%
-37.82%
-81.28%
-95.69%
-49.88%
-74.05%
-19.27%
1.38%
11.96%
21.83%
-4.38%
31.49%
18.40%
28.71%
-8.67%
-32.14%
-14.98%
115.7%
50.55%
197.1%
-31.74%
65.37%
-32.44%
-44.04%
-68.72%
-60.09%
-83.95%
-24.91%
3.66%
32.47%
-27.18%
-59.29%
-4.23%
-63.31%
123.4%
107.8%
17.32%
103.1%
-15.24%
--
-48.47%
-89.99%
-52.12%
161.9%
116.9%
19.03%
-41.27%
As of January 26, 2022.

Profile

Edit
Liminal Biosciences Inc engages in clinical-stage research and commercialization of fibrosis treatments. The company operates in two segments: Small molecule therapeutics and Plasma-derived therapeutics. The Small molecule segment develops and commercializes treatments for lung, liver, and kidney conditions. The Plasma-derived segment sells proteins and specialty plasma in addition to developing a plasma treatment product. Liminal Biosciences does business in Canada, the U.K., and the U.S., and nearly all of its revenue comes from the plasma-derived therapeutics segment.
URL https://www.liminalbiosciences.com
Investor Relations URL http://www.prometic.com/investors/
HQ State/Province Quebec
Sector Healthcare
Industry Biotechnology
Equity Style Small Cap/Value
Next Earnings Release Mar. 24, 2022
Last Earnings Release Nov. 15, 2021
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Top Fund Holders

No data available
Symbol Dollars Invested % Weight
     
     
     
     
     
     
     
     
     
     

Top Portfolio Holders

0 of 0

Other Resources

Whale Wisdom 13F Filings
Seeking Alpha Call Transcripts
Morningstar Insider Trading
Nasdaq Institutional Ownership
Nasdaq Option Chain
SEC SEC Filings
Stocktwits LMNL Tweets